Cellular Biomedicine will provide China manufacturing services for a Novartis CAR-T cell therapy, Kymriah®. Novartis will buy $40 million of CBMG stock, while CBMG will manufacture the individual doses of the therapy at a profit and be paid royalties. Novartis will retain China marketing rights and also receive rights to some CBMG technologies for CAR-T manufacturing. Kymriah, which was approved in the US one year ago to treat acute lymphoblastic leukemia, is not yet approved for use in China . More details.... Stock Symbols: (NSDQ: CBMG) (NYSE: NVS) Share this with colleagues: // //